Zacks Research Has Negative Outlook of Alkermes Q2 Earnings

Alkermes plc (NASDAQ:ALKS) – Investment analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for Alkermes in a research note issued on Monday, January 6th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.31 per share for the quarter, down from their previous forecast of $0.33. The consensus estimate for Alkermes’ current full-year earnings is $2.25 per share. Zacks Research also issued estimates for Alkermes’ Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at $0.35 EPS and FY2026 earnings at $1.56 EPS.

A number of other research analysts also recently commented on ALKS. The Goldman Sachs Group dropped their target price on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. Mizuho boosted their target price on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. Finally, Cantor Fitzgerald cut their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Alkermes presently has an average rating of “Moderate Buy” and an average target price of $36.00.

Alkermes Stock Down 0.4 %

ALKS stock opened at $28.42 on Wednesday. The stock has a market cap of $4.60 billion, a P/E ratio of 14.57, a PEG ratio of 1.03 and a beta of 0.49. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. Alkermes has a twelve month low of $22.90 and a twelve month high of $32.88. The company’s 50 day moving average is $29.21 and its two-hundred day moving average is $27.63.

Hedge Funds Weigh In On Alkermes

A number of institutional investors and hedge funds have recently made changes to their positions in ALKS. V Square Quantitative Management LLC purchased a new stake in Alkermes during the third quarter worth about $29,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alkermes during the 2nd quarter valued at approximately $116,000. GAMMA Investing LLC boosted its stake in shares of Alkermes by 83.8% during the 3rd quarter. GAMMA Investing LLC now owns 4,204 shares of the company’s stock worth $118,000 after acquiring an additional 1,917 shares in the last quarter. Archer Investment Corp grew its holdings in shares of Alkermes by 28.6% in the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after acquiring an additional 1,000 shares during the period. Finally, KBC Group NV increased its stake in Alkermes by 18.8% in the 3rd quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after purchasing an additional 774 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alkermes

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the transaction, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Craig C. Hopkinson sold 10,471 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the sale, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at $2,930,498.14. This represents a 9.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 147,738 shares of company stock valued at $4,572,904. 4.89% of the stock is owned by company insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.